What's Happening

Indicated to improve glycemic control for type 1 and 2 diabetes

The 7th biosimilar approved for adalimumab. For the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s Disease, ulcerative colitis, and plaque psoriasis

Indicated for the treatment of seizures, and for the preventive treatment of migraine

Indicated for the treatment of opioid-induced constipation

Indicated for the emergency treatment of known or suspected opioid overdose

A combination opioid agonist and NSAID indicated for the management of acute pain severe enough to require an opioid and for which alternative treatments are inadequate

A biosimilar to Humira, this drug is now officially interchangeable with Humira for the treatment  of moderate-to-severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, moderate-to-severe Crohn’s disease, moderate-to-severe ulcerative colitis, and moderate-to-severe chronic plaque psoriasis

Indicated for the treatment of major depressive disorder, obsessive compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, and PTSD

Indicated for the treatment of major depressive disorder (MDD)

Indicated for the acute treatment of migraine with or without aura